“Challenges which others have deemed unsolvable are the problems we are solving.”
~ Jeffrey S. Aronin
Paragon founder, chairman and CEO
Portfolio
Since 2017, Paragon has successfully launched seven portfolio companies, including a recent upsized IPO, while maintaining a consistent flow of companies in development.
Leveraging its proprietary fibroblast technology platform to expand an innovative gene therapy pipeline, developing personalized treatments for underserved disorders, including epidermolysis bullosa and localized scleroderma.
Creating treatments for central nervous system movement disorders and fluency disorders, including Tourette syndrome and childhood-onset fluency disorder (stuttering) in adults.
Evozyne is combining the exquisite complexity of nature with advanced machine learning to create novel proteins with extraordinary impact across a variety of industries.
Commercializing biopharmaceutical treatment options for people living with rare diseases, including disorders of sleep and wakefulness, such as narcolepsy, Prader-Willi syndrome and myotonic dystrophy.
Assisting radiologists to significantly improve clinical assessment and characterization of cancerous breast abnormalities through artificial intelligence-driven technology that enhances clinical insights.
News
Outstanding First Half for Paragon and its Portfolio Companies
Paragon and its portfolio companies continue to successfully advance biology-based innovation, creating impressive results. First Half 2022 Newsletter We are a global life science leader that creates, builds [...]
Castle Creek Biosciences Raises $112.8 Million to Advance Novel Gene Therapies and Expand Pipeline
– Funding expected to provide sufficient capital for completion of Phase 3 trial for ex vivo product candidate for recessive dystrophic epidermolysis bullosa and to advance in vivo candidate for [...]
Evozyne Announces Multi-Target Research Collaboration and License Agreement with Takeda to Develop Next-Generation Gene Therapies
Expansion builds on initial strategic collaboration and license agreement Chicago, April 5, 2022 – Evozyne, Inc., an adaptive biology company pioneering evolution-based design of proteins, founded [...]
Outstanding First Half for Paragon and its Portfolio Companies
Paragon and its portfolio companies continue to successfully advance biology-based innovation, creating impressive results. First Half 2022 Newsletter We are [...]
Castle Creek Biosciences Raises $112.8 Million to Advance Novel Gene Therapies and Expand Pipeline
– Funding expected to provide sufficient capital for completion of Phase 3 trial for ex vivo product candidate for recessive dystrophic epidermolysis [...]
Evozyne Announces Multi-Target Research Collaboration and License Agreement with Takeda to Develop Next-Generation Gene Therapies
Expansion builds on initial strategic collaboration and license agreement Chicago, April 5, 2022 – Evozyne, Inc., an adaptive [...]
Outstanding First Half for Paragon and its Portfolio Companies
Paragon and its portfolio companies continue to successfully advance biology-based innovation, creating impressive results. First Half 2022 Newsletter We are [...]
Castle Creek Biosciences Raises $112.8 Million to Advance Novel Gene Therapies and Expand Pipeline
– Funding expected to provide sufficient capital for completion of Phase 3 trial for ex vivo product candidate for recessive dystrophic epidermolysis [...]
Evozyne Announces Multi-Target Research Collaboration and License Agreement with Takeda to Develop Next-Generation Gene Therapies
Expansion builds on initial strategic collaboration and license agreement Chicago, April 5, 2022 – Evozyne, Inc., an adaptive [...]